Freeline Therapeutics Holdings is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company. Co. is engaged in developing one-time gene therapy treatments that provide functional cures through permanently sustained physiological protein levels. Co.'s most advanced product candidate, FLT180a, is intended for the treatment of patients in whom a deficiency of functional clotting FIX, causes moderate or severe hemophilia B. Co.'s second product candidate, FLT190, is being developed for the treatment of Fabry disease. Co. is also developing third and fourth product candidates, FLT201 and FLT210, for the treatment of Gaucher disease and hemophilia A. The FRLN stock yearly return is shown above.
The yearly return on the FRLN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FRLN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|